Summary
From January 1978 to December 1980, 222 patients with metastatic breast cancer were included into a prospective multicenter trial. All patients were treated once a month with six cycles of VAC- (vincristine, adriamycin, cyclophosphamide) chemotherapy, followed by FMC (5-fluor-ouracil, methotrexate, cyclophosphamide) until progression was documented. By random assignment, the patients received immunostimulation with Corynebacterium parvum (CP) by one of four methods: subcutaneous (SC) on either day 1 or day 14, intravenous (IV) on either day 1 or day 14. The 214 evaluable patients were equally distributed to the four arms. The rates of complete or partial response to VAC/FMC plus CP did not differ significantly between the treatment groups. Of our patients, 22–33% were definite treatment failures. The Kaplan-Meier curves of duration of remission (medians 14 vs. 9 vs. 13 vs. 11 months) did not differ significantly. Only small differences in survival were noted among the four study groups (medians 15.4 vs. 17.5 vs. 17.2 vs. 13.0 months). However, complete and partial responders lived significantly longer (Log rank testP=0.008), when CP was given on day 14 by the SC rather than IV route (29+ vs. 14.3 months). Patients in the four study groups were treated with virtually identical doses of VAC/FMC chemotherapy. Patients receiving CP intravenously on day 14 experienced significantly lower mean leukocyte counts than patients in the other groups. Many patients suffered from high temperature (requiring treatment with antipyretics) and severe gastrointestinal toxicity, particularly when CP was given IV on day 1 together with the chemotherapy. Sixteen patients developed skin ulcers following repeated SC injections of CP. They showed a 4-month longer median survival than patients without these local reactions. Taken together, the results suggest that adding CP in the ways tested to monthly VAC/FMC chemotherapy is of no benefit to patients with metastatic breast cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Milas L, Scott MT (1978) Antitumor effect of Corynebacterium parvum. Adv Cancer Res 26:257
Halpern BN, Biozzi G, Stiffel G, Mouton D (1966) Inhibition of tumor growth by administration of killed Corynebacterium parvum. Nature 212:853–854
Woodruff MFA, Boak JL (1976) Inhibitory effect of injection of Corynebacterium parvum on the growth of tumour transplants in isogenic hosts. Br J Cancer 20:345–355
Sadler TE, Castro JE (1976) The effects of Corynebacterium parvum and surgery on the Lewis lung carcinoma and its metastases. Br J Surg 63:292–296
Israel L, Edelstein R (1977) Personal experience with Corynebacterium parvum in human cancers. World J Surg 1:585–594
Pinsky CM, DeJager RL, Wittes RE, Wong PP, Kaufman RJ, Mike V, Hansen JA, Oettgen HF, Krakoff IH (1978) Corynebacterium parvum as adjuvant to combination chemotherapy in patients with advanced breast cancer: preliminary results of a prospective randomized trial. In: Terry WD, Windhorst D (eds) Immunotherapy of cancer: Present status of trials in man. Raven Press, New York, pp 647–654
Mayr AC, Senn HJ, Gallmeier WM, Bruntsch U, Becher R, Drings P, Fritze D, Kaufmann M, Queißer W, Kempgens U (1979) Adriamycin-Kombinations-Chemotherapie mit oder ohne Immunstimulation durch Corynebacterium parvum beim metastasierenden Mammakarzinom. Dtsch Med Wochenschr 104:1739–1743
Fritze D, Becher R, Massner B, Kaufmann M, Bruntsch U, Gallmeier WM, Mayr AC, Drings P, Abel U, Edler L, Jungi WF, Queißer W, Senn HJ (1982) A randomized study of combination chemotherapy (VAC-FMC) with or without immunostimulation by Corynebacterium parvum in metastatic breast cancer. Klin Wochenschr 50:593–598
Peto R, Pike C, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG (1976) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 34:585–612
Peto R, Pike C, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 35:1–39
Krown SE, Pinsky CM, Wanebo HJ, Braun DW, Wong PP, Oettgen HF (1980) Immunologic reactivity and prognosis in breast cancer. Cancer 46:1746–1752
Thatcher N, Lamb B, Swindell R, Crowther D (1981) Effects of Corynebacterium parvum on cellular immunity of cancer patients, assayed sequentially over 63 days. Cancer 47:285–290
Williams CJ (1982) Immunotherapy reassessed. Br Med J 284:920–921
Edler L, Abel U, Fritze D, Maßner B, Becher R, Kaufmann M, Hartlapp J, Illiger HJ, Queißer M, Mayr AC, Drings P, Westerhausen M, Jungi WF, Senn HJ (1983) Statistical evaluation of the multicenter metastatic breast cancer trial (11/77). Technical Report 2/83. Department of Biostatistics, German Cancer Research Center, Heidelberg
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fritze, D., Massner, B., Becher, R. et al. Combination chemotherapy (VAC/FMC) with immunostimulation in metastatic breast cancer: A randomized study comparing different times and routes of administration of corynebacterium parvum. Klin Wochenschr 62, 162–167 (1984). https://doi.org/10.1007/BF01731638
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01731638